NEW YORK — — With a focus on making the transition to a more secure, effective and affordable vaccine, Cephalon Biomedical Co. today announced it has signed a contract with the U.S. Food and Drug Administration (FDA) to establish a new company-owned and-operated vaccine testing and certification program for its newly launched cbaptide vaccine.
The U.K.-based company, which has received a total of more than $3 billion in investment funding, said it is seeking accredited testing labs to test its cbapedib vaccine.
CBAP, which stands for Combination Biodefense-Antibody, is a biologics regulatory agency that certifies the safety and efficacy of vaccines, and is the world’s largest independent provider of vaccine testing services.
The company, with headquarters in London, said its new certification program is the first of its kind for a biologic vaccine.
“We are thrilled to partner with the FDA to ensure that our cbaps are being tested and certified by accredited laboratories,” said Cepha Laboratories Chief Executive Officer Steve Wilson.
About CBAP:Cepha Labs has more than 15,000 customers globally, and employs nearly 10,000 people in the U-K.
CBP is a member of the UGC Alliance, the largest industry association for the testing and certifying of vaccines.
SOURCE Cephas Biomedical Company, Inc.
For further information:Cbaptides Inc.
Phone: 070 934 7555Cbap Laboratories Inc. Phone: 020 707 5444Cephalons Biomedical GroupPhone: 0320 918 7888For further details: Cephals Biomedical Inc. (www.cbap.com) press release: Tags cbAP antibody,bbap certification,certification,accredited,vaccine source Bloomberg news title Cephala to acquire bbap certification firm CBAP source Bloomberg May 25, 2018 08:58:26